BRISTOL MYERS SQUIBB

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive

Phase 2

Terminated

Conditions: HIV-1 Infection

Interventions: Drug: BMS-986001
Drug: Placebo matching with BMS-986001
Drug: Lamivudine
Drug: Tenofovir
Drug: Efavirenz

First Posted Date: 2011-12-09

Last Posted Date: 2016-04-15

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 297

Registration Number: NCT01489046

Locations: 🇺🇸
Orlando Immunology Center, Orlando, Florida, United States
🇺🇸
Jacobi Medical Center, Bronx, New York, United States
🇹🇭
Local Institution, Nontaburi, Thailand

and more 12 locations

Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma

Phase 1

Completed

Conditions: Melanoma

Interventions: Biological: BMS-982470 (recombinant interleukin-21)
Biological: Ipilimumab

First Posted Date: 2011-12-09

Last Posted Date: 2014-08-29

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 42

Registration Number: NCT01489059

Locations: 🇺🇸
Oncology Research Associates, Pllc D/B/A, Scottsdale, Arizona, United States
🇺🇸
Ucla Hematology/Oncology., Los Angeles, California, United States
🇺🇸
Indiana University Health Melvin And Bren Simon Cancer Center, Indianapolis, Indiana, United States

and more 6 locations

Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Biological: Elotuzumab
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2011-11-23

Last Posted Date: 2018-05-21

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 185

Registration Number: NCT01478048

Locations: 🇺🇸
Cancer Center Of Acadiana, Lafayette, Louisiana, United States
🇺🇸
Medical University Of South Carolina, Charleston, South Carolina, United States
🇺🇸
Ucla Department Of Medicine, Los Angeles, California, United States

and more 28 locations

Patterns of Use of Belatacept: Analysis of Data From the Collaborative Transplant Study

Completed

Conditions: Transplantation, Organ

First Posted Date: 2011-11-22

Last Posted Date: 2018-05-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 72392

Registration Number: NCT01476943

Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)

Phase 1

Completed

Conditions: Renal Cell Carcinoma
Clear-cell Metastatic Renal Cell Carcinoma

Interventions: Biological: Nivolumab
Biological: Pazopanib
Biological: Ipilimumab
Drug: Sunitinib

First Posted Date: 2011-11-16

Last Posted Date: 2021-12-02

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 194

Registration Number: NCT01472081

Locations: 🇺🇸
City Of Hope, Duarte, California, United States
🇺🇸
Memorial Sloan Kettering Nassau, New York, New York, United States
🇺🇸
Blumenthal Cancer Center, Charlotte, North Carolina, United States

and more 11 locations

Study Investigating the Pharmacokinetic Interaction Between INX-08189 and Verapamil HCL ER in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: INX-08189 50 mg
Drug: 240 mg verapamil HCL ER
Drug: 50 mg dose of INX-08189 and 240 mg verapamil HCL ER

First Posted Date: 2011-11-16

Last Posted Date: 2012-06-22

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 24

Registration Number: NCT01471704

Locations: 🇺🇸
Prism Research, LLC, St Paul, Minnesota, United States

Study to Evaluate the Pharmacokinetics and Safety of INX-08189 Administered With VictrelisTM in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: INX-08189 / Victrelis 800 mg TID X three days
Drug: Victrelis 800 mg TID x 3 days
Drug: INX-08189 50 mg QD X 5 days
Drug: Victrelis 800 mg TID with INX-08189 50 mg QD
Drug: Placebo with Victrelis 800 mg

First Posted Date: 2011-11-16

Last Posted Date: 2012-06-22

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 32

Registration Number: NCT01471717

Locations: 🇺🇸
Prism Research, LLC, St Paul, Minnesota, United States

Safety and Efficacy Trial of Ipilimumab Versus Pemetrexed in Non-Squamous Non-Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Lung Cancer - Non Small Cell

Interventions: Biological: Ipilimumab
Biological: Pemetrexed

First Posted Date: 2011-11-15

Last Posted Date: 2014-05-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 9

Registration Number: NCT01471197

Locations: 🇺🇸
Marin Specialty Care, Inc., Greenbrae, California, United States
🇺🇸
Medical And Surgical Specialists, Llc, Galesburg, Illinois, United States
🇺🇸
Quincy Medical Group, Quincy, Illinois, United States

and more 5 locations

Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Phase 1

Completed

Conditions: Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma

Interventions: Drug: Urelumab (BMS-663513)

First Posted Date: 2011-11-15

Last Posted Date: 2017-04-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 124

Registration Number: NCT01471210

Locations: 🇺🇸
Division Of Hematology & Oncology Ctr. For Health Sciences, Los Angeles, California, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States

and more 12 locations

Belatacept in Renal Transplantation: Analyses Using Data From the Collaborative Transplant Study

Completed

Conditions: Kidney Transplantation

First Posted Date: 2011-11-15

Last Posted Date: 2017-09-19

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 89

Registration Number: NCT01471223

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy